--- title: "Akeso Proposes Additional On-Market Share Purchases" type: "News" locale: "en" url: "https://longbridge.com/en/news/305840563.md" description: "Akeso's board approved an additional HK$200 million for on-market share purchases, funded by existing cash. The trustee of the 2021 restricted share unit scheme will execute these buys. The board stated that the current trading price undervalues the company and aims to demonstrate confidence in its business outlook." datetime: "2026-11-17T13:37:36.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/305840563.md) - [en](https://longbridge.com/en/news/305840563.md) - [zh-HK](https://longbridge.com/zh-HK/news/305840563.md) generator: "portal-rs" --- # Akeso Proposes Additional On-Market Share Purchases Akeso, Inc. ( (HK:9926) ) has issued an update. Akeso’s board approved the use of up to an additional HK$200 million for proposed on-market purchases of the company’s shares. The purchases would be conducted by the trustee of its 2021 restricted share unit scheme and funded from existing available cash resources. The board said the current trading price does not reflect the company’s intrinsic value and growth potential, and that the proposed purchases demonstrate the confidence of the board and management in the business outlook and prospects. Shareholders and potential investors were advised to exercise caution when dealing in the company’s securities. ### Related Stocks - [09926.HK](https://longbridge.com/en/quote/09926.HK.md) ## Related News & Research - [Akeso Says FDA Complete Response Letter May Explain Unusual Share Price Moves](https://longbridge.com/en/news/305612661.md) - [China Accepts Akeso’s Ivonescimab Application for Biliary Tract Cancer](https://longbridge.com/en/news/305757945.md) - [Akeso's Gumokimab Wins China Approval for Active Ankylosing Spondylitis](https://longbridge.com/en/news/305622467.md) - [Nomura Downgrades AKESO to Neutral, Cuts TP to HKD94](https://longbridge.com/en/news/305613245.md) - [UBS: AKESO Partner Receives FDA Complete Response Letter for ivonescimab Plus Chemotherapy BLA, Slightly Negative](https://longbridge.com/en/news/305605601.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**